AL16ALA-SOD2 polymorphism predicts recurrence risk of breast cancer in patients treated with adjuvant tamoxifen-Reference-Cited by-同舟云学术

AL16ALA-SOD2 polymorphism predicts recurrence risk of breast cancer in patients treated with adjuvant tamoxifen

Published:2023-10 Issue: Volume:8 Page:100108
ISSN:2667-3940
Container-title:Advances in Cancer Biology - Metastasis
language:en
Short-container-title:Advances in Cancer Biology - Metastasis

Author:

Dal Berto Maiquidieli,Martin Manfroi Laura^ORCID,Vieira dos Santos Aniúsca,Tavares dos Santos Giovana,Krüger da Costa Gabriela,Macedo Boaro Camila,Rigon Péttala,Vargas Alves Rafael José,Giuliano Bica Claudia

Funder

Coordenação de Aperfeiçoamento de Pessoal de Nível Superior

Conselho Nacional de Desenvolvimento Científico e Tecnológico

Universidade Federal de Ciências da Saúde de Porto Alegre

Foundation for Research Support of Rio Grande do Sul State

Publisher

Elsevier BV

Subject

Cancer Research,Cell Biology

Reference50 articles.

1. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries;Sung;Ca - Cancer J. Clin.,2021

2. The natural history of hormone receptor-positive breast cancer;Lim;Oncology (Williston Park),2012

3. Selective estrogen receptor modulators;An;Asian Spine J,2016

4. Tamoxifen: a most unlikely pioneering medicine;Jordan;Nat. Rev. Drug Discov.,2003

5. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials;Early Breast Cancer Trialists' Collaborative;Lancet,2011

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The impact of the association between Val16Ala-SOD2 SNP and SOD2 immunohistochemistry expression in the prognosis of patients with esophageal cancer;Pathology - Research and Practice;2024-01